Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI-generated claim that the JANUMET WARNING: LACTIC ACIDOSIS content is supported by the FDA label is consistent with the provided label excerpts, including recognition, risk factors, contraindications, management (immediate discontinuation and prompt hemodialysis), and related precautions.
Category Scores
Accurate Statements
“WARNING: LACTIC ACIDOSIS (metformin-associated lactic acidosis risk, recognition, and management in JANUMET label)”
Supported by Warnings and Precautions (5.1 Lactic Acidosis) in the provided label excerpt, including postmarketing fatal cases, symptom recognition, diagnostic characterization, and management steps (immediate discontinuation and prompt hemodialysis).
The warning content described is directly included in the JANUMET FDA label (Warnings and Precautions 5.1) and related sections for risk factors and management.
Consistent with provided excerpts from 5.1 and related risk-factor/management sections (renal impairment, contrast procedures, drug interactions/alcohol, hepatic impairment, and patient counseling).
The AI’s cited label alignment includes contraindication in acute or chronic metabolic acidosis including diabetic ketoacidosis.
Supported by Contraindications (4) excerpt: “Acute or chronic metabolic acidosis, including diabetic ketoacidosis.”
Renal impairment precautions tied to lactic acidosis risk (eGFR threshold contraindication and monitoring).
Supported by Recommendations for Use in Renal Impairment (2.2) and Warnings and Precautions (5.1) excerpt.
Contrast-procedure discontinuation/restart guidance related to lactic acidosis risk via renal function.
Supported by Discontinuation for Iodinated Contrast Imaging Procedures (2.3) excerpt.
Alcohol warning and drug interaction risks that may increase lactic acidosis risk (e.g., carbonic anhydrase inhibitors; drugs that reduce metformin clearance).
Supported by Drug Interactions (7) excerpt including alcohol intervention and examples listed for lactic acidosis risk.
JANUMET is not recommended in hepatic impairment due to association with lactic acidosis.
Supported by Hepatic Impairment (8.7) excerpt and referenced content in 5.1.
Patient counseling includes symptom recognition and instructions to discontinue JANUMET and notify provider; counsel against excessive alcohol intake; importance of renal function testing; inform doctor prior to surgical/radiological procedures.
Supported by Patient Counseling Information (17) excerpt.
Unsupported Statements
Contradictions
Important Omissions
No explicit omission identified, because the evaluated output is a high-level assertion of label support and does not include specific dosing, contraindication details beyond what was cited, or safety outcomes beyond what is already referenced as being in the label.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The response does not provide patient-specific medical advice or dosing instructions; it only states that the lactic acidosis warning content is supported by the label. Provided label excerpts support the referenced warning and related precautions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement